Establishment and application of hepatitis B virus persistent replication model in IFNAR-/- mouse

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 33, Issue 3, 2013, Pages 392-397

  Chen, Ming Fa ^a,b   Lin, Yong ^a   Xia, You Chen ^a   Sun, Chan ^a   Feng, Xue Mei ^a   Lu, Meng Ji ^c   Yang, Dong Liang ^a   Wu, Jun ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b NANCHANG UNIVERSITY   (China)

^c UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

Author keywords

animal model; chronic hepatitis B; IFNAR mouse; type I Interferon; type I interferon receptor (IFNAR)

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR;

ANIMAL; ARTICLE; C57BL MOUSE; CHRONIC DISEASE; DISEASE MODEL; FEMALE; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KNOCKOUT MOUSE; MALE; METABOLISM; MOUSE; PHYSIOLOGY; VIROLOGY; VIRUS REPLICATION;

ANIMALS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTOR, INTERFERON ALPHA-BETA; VIRUS REPLICATION;

EID: 84879288480     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-013-1130-y     Document Type: Article

References (30)

1. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol, 2005,34(Suppl 1):S1-3
2. Lai CL, Ratziu V, Yuen MF, et al. Viral hepatitis B. Lancet, 2003,362(9401):2089-2094
3. Bhattacharya D, Thio CL. Review of hepatitis B therapeutics. Clin Infect Dis, 51(10):1201-1208
4. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science, 1994,264(5164):1415-1421
5. Huang LR, Wu HL, Chen PJ, et al. An immunocompetent mouse model for the tolerance of human chronic hepatitis B virus infection. Proc Natl Acad Sci U S A, 2006,103(47):17862-17867
6. Gao Z, Liu FJ, Liu L, et al. Application of hepatitis B virus replication mouse model. World J Gastroenterol, 2010,16(16):1979-1985
7. Chen Y, Wu W, Li LJ, et al. Comparison of the results for three automated immunoassay systems in determining serum HBV markers. Clin Chim Acta, 2006,372(1-2): 129-133
8. Yeh SH, Tsai CY, Kao JH, et al. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol, 2004,41(4):659-666
9. Detre S, Saclani Jotti G, Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol, 1995,48(9):876-878
10. Wang BJ, Bao JJ, Wang JZ, et al. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World J Gastroenterol, 17(28): 3322-3329
11. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene therapy, 1999,6(7):1258-1266
12. Yang PL, Althage A, Chung J, et al. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci U S A, 2002,99(21): 13825-13830
13. Suzuki T, Takehara T, Ohkawa K, et al. Intravenous injection of naked plasmid DNA encoding hepatitis B virus (HBV) produces HBV and induces humoral immune response in mice. Biochem Biophys Res Commun, 2003,300(3):784-788
14. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev, 2004,202:8-32
15. Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science, 2002,296(5573): 1653-1655
16. Der SD, Zhou A, Williams BR, et al. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A, 1998,95(26):15623-15628
17. Hansen BE, Buster EH, Steyerberg EW, et al. Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment. J Med Virol, 2010,82(7): 1135-1142
18. Tian Y, Chen WL, Ou JH. Effects of interferon-alpha/beta on HBV replication determined by viral load. PLoS Pathog, 7(7):e1002159
19. Zhou J, Huang JD, Poon VK, et al. Functional dissection of an IFN-alpha/beta receptor 1 promoter variant that confers higher risk to chronic hepatitis B virus infection. J Hepatol, 2009,51(2):322-332
20. Zhou J, Lu L, Yuen MF, et al. Polymorphisms of type I interferon receptor 1 promoter and their effects on chronic hepatitis B virus infection. J Hepatol, 2007,46(2): 198-205
21. He XX, Chang Y, Jiang HJ, et al. Persistent effect of IFNAR-1 genetic polymorphism on the long-term pathogenesis of chronic HBV infection. Viral Immunol, 23(3): 251-257
22. Meng F, Wang J, Ge J, et al. Alteration of interferon-alpha/beta receptors in chronic hepatitis B patients. J Clin Immunol, 31(3):521-532
23. Song CH, Yang B, Chen LM, et al. IL-10 and IFN-γ serum changes during treatment of chronic HBV infection patients with ETV. Weichangbing Xue He Ganbing Xue Zazhi (Chinese), 2010,19(12):1114-1116
24. Yin L, Qiao WB, Qu XJ, et al. The study of interferon induced by nucleoside analogues. Shandong Yiyao (Chinese), 1996,36(6): 5-6
25. Bhattacharya D, Thio CL. Review of hepatitis B therapeutics. Clin Infect Dis, 2010,51(10):1201-1208
26. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med, 2006,354(10):1011-1020
27. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med, 2006,354(10):1001-1010
28. Wu J, Lu M, Meng Z, et al. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology, 2007,46(6):1769-1778
29. Wu J, Meng Z, Jiang M, et al. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology, 2009,49(4):1132-1140
30. Broering R, Wu J, Meng Z, et al. Toll-like receptor-stimulated non-parenchymal liver cells can regulate hepatitis C virus replication. J Hepatol, 2008,48(6): 914-922